Novel Therapy Target in Metastatic Prostate Cancer

Recruiting now

Conditions studied: Prostate Neoplasms

In brief

The aim of this study is to use multiomics sequencing to explore the molecular characteristics of metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC). At the same time, mCRPC models will be constructed, including organoids and animal models, serving as a basic and translational research platform to help identify novel drug targets for mPCa.

Key facts

Study ID

NCT05577689

Run by

Fudan University

People needed

100

Starts

2023-08-01

Expected to finish

2028-12-01

Last updated by the study team

2025-06-05

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed prostate cancer
• metastatic disease confirmed by image examination
• Patients who can undergo surgery or biopsy for prostate cancer
• Able to provide informed consent

You may not qualify if…

• Patients diagnosed with other types of cancer besides prostate cancer
• Not accessible to surgery sample
• Patients fail to provide informed consent
• Other situation that researchers think are unsuitable for this study

Where it is running

• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.